Experience

Div Gupta

    • Ascendis Pharma – $575 Million Convertible Senior Notes Offering 


    • argenx – $805 Million Follow-On Offering 


    • CinCor Pharma – $212 Million IPO 


    • Alvotech Agrees to Merge With SPAC Oaktree Acquisition Corp. II 


    • Exscientia – $510.4 Million IPO 


    • Ascendis Pharma – $460 Million Follow-On Offering 


    • Adagio Therapeutics – $356 Million IPO 


    • MaxCyte – $202 Million IPO 


    • SOPHiA Genetics – $234 Million IPO 


    • Elevation Oncology – $107 Million IPO 


    • GH Research – $184 Million IPO 


    • Verve Therapeutics – $307 Million IPO 


    • Molecular Partners – $64 Million IPO 


    • Centessa Pharmaceuticals – $380 Million IPO 


    • Adagio Therapeutics Raises $336 Million Series C for COVID-19 Treatment and Prevention 


    • Talaris Therapeutics – $150 Million IPO 


    • Werewolf Therapeutics – $120 Million IPO 


    • VectivBio – $147 Milion IPO 


    • Finch Therapeutics – $128 Million IPO 


    • Immunocore $312.1 Million Aggregate Financing 


    • Edgewise Therapeutics – $202 Million IPO 


    • LAVA Therapeutics – $107 Million IPO 


    • Instil Bio – $368 Million IPO 


    • NexImmune – $127 Million IPO 


    • Immunocore – $297 Million IPO 


    • Vor Biopharma – $203 Million IPO  


    • Landos Biopharma – $100 Million IPO 


    • Turnstone Biologics to Acquire Myst Therapeutics 


    • Nanobiotix – $113 Million IPO 


    • Ovid - $75 Million IPO 


    • Opthea – $128 Million IPO 


    • Prelude – $182 Million IPO 


    • C4 Therapeutics – $210 Million IPO 


    • Taysha Gene Therapies – $181 Million IPO 


    • Orphazyme – $84 Million IPO 


    • COMPASS Pathways – $147 Million IPO 


    • Prelude Therapeutics – $182 Million IPO 


    • Dyne Therapeutics – $268 Million IPO 


    • Silence Therapeutics – Direct Listing  


    • ADC Therapeutics – $233 Million IPO 


    • iTeos Therapeutics – $201 Million IPO 


    • Inventiva – $108 Million IPO 


    • Akouos – $244 Million IPO 


    • PolyPid – $69 Million IPO 


    • Repare Therapeutics - $253 Million IPO 


    • Avidity Biosciences - $289 Million IPO 


    • Calliditas Therapeutics - $90 Million IPO 


    • Legend Biotech - $487 Million IPO 


    • Imara - $75 Million IPO 


    • Bavarian Nordic - DKK$2.7 Billion Rights Issue 


    • Shake Shack - $215 Million Combined Secondary Offerings 


    • Zentalis Pharmaceuticals - $190 Million IPO 


    • Passage Bio - $216 Million IPO 


    • Schrodinger - $202 Million IPO 


    • Reata Pharmaceuticals – $505 Million Follow-On Offering 


    • argenx – $557 Million Follow-On Offering 


    • Prevail Therapeutics Closes $50 Million Series B 


    • Innate Pharma - $79 Million IPO 


    • SpringWorks Therapeutics – $186 Million IPO  


    • Bellus Health – $70 Million IPO  


    • Karuna Therapeutics $103 million IPO 


    • Morphic Therapeutics - $104 Million IPO 


    • Akero Therapeutics - $106 Million IPO 


    • Prevail Therapeutics $125 Million IPO 


    • Bicycle Therapeutics - $61 Million IPO 


    • Milestone Pharmaceuticals – $95 Million IPO 


    • Applied Therapeutics $40 Million IPO 


    • NextCure – $86 Million IPO 


    • Precision BioSciences $145 Million IPO 


    • Neuronetics – $108 Million IPO 


    • Stealth BioTherapeutics $78 Million IPO 


    • Gamida Cell – $50 Million IPO 


    • LogicBio Therapeutics – $80.5 Million IPO 


    • AGNC Closes $507.2 Million Mortgage REIT Equity Offering 


    • Eidos Therapeutics – $122 Million IPO 


    • MeiraGTx – $75 Million IPO 


    • Verrica Pharmaceuticals – $86 Million IPO 


    • ERYTECH – $144 Million IPO 


    • Cooley Advises on Nightstar + NuCana IPOs 


    • Zealand Pharma – $89 Million IPO 


    • Neon Therapeutics – $100 Million IPO 


    • UroGen – $66.9 Million IPO 


    • Verona – $80 Million IPO 


    • ERYTECH Closes €70.5 Million Private Placement to US + European Investors 


    • Recro Pharma – $15 Million Follow-On  


    • Advaxis – $30 Million Registered Direct Offering 


    • Gemphire Therapeutics – $30 Million IPO 


    • Syros – $58 Million IPO 


    • Syros IPO – $58 Million 


    • Selecta Biosciences – $74 Million IPO 


    • Tricida – $256 Million IPO 


    • Translate Bio – $122 Million IPO 


    • Oncobiologics – $40 Million IPO and Private Placement 


    • Inotek Pharmaceuticals – $50 Million Follow-On 


    • Syndax – $58 Million IPO 


    • AveXis – $95 Million IPO 


    • Cooley Advises ERYTECH on €25.4 Million Private Placement 


    • ERYTECH Private Placement 


    • Strongbridge Biopharma IPO 


    • Aclaris Therapeutics IPO 


    • ProNAi Therapeutics - $158 Million IPO 


    • Chiasma Completes $117 Million IPO 


    • Celyad Completes IPO 


    • Immunocore Limited Series A $320 Million Financing 


    • Cooley Advises Immunocore on Largest European Private Life Sciences Financing on Record 


    • Catabasis Completes $69 Million IPO 


    • ProNAi – $158 Million IPO 


    • DBV Technologies – $281.5 Million Follow-On Offering  


    • Axovant Completes $362 Million IPO 


    • Ascendis Pharma closes $124 million IPO 


    • Bellicum Pharmaceuticals $160 million IPO 


    • DBV Technologies Completes Concurrent Public Offerings 


    • Cooley's Capital Markets Leadership Continues through 1H 2014 


    • T2 Biosystems IPO 


    • Vitae Pharmaceuticals Completes Initial Public Offering  


    • Immune Design $63 Million Initial Public Offering 


    • OnCore Biopharma Announces Merger Agreement with Tekmira Pharmaceuticals 


    • Merus IPO – $61 Million 


    • AbCellera Biologics - $556 million IPO